Proactive Investors - Run By Investors For Investors

e-Therapeutics and C4x Discovery team up to find new Parkinson’s treatments

By combining both of their technologies, the companies think they can identify better treatments for Parkinson’s disease
elderly man
The combination could also help find new treatments for disorders such as Alzheimer’s and MS

e-Therapeutics PLC (LON:ETX) has teamed up with C4X Discovery Holdings plc (LON:C4XD) in a bid to find new treatments for Parkinson’s disease.

Parkinson’s is a long-term degenerative disorder, with typical symptoms including shaking and slowness of movement.

There is currently no cure for the disease, with treatments aimed instead at improving symptoms, albeit with limited success.

READ: ETX sees biopharma sector get in tune with its way of thinking

C4X’s Taxonomy-3 platform uses sophisticated algorithms that run over genetic data time and again to identify the genes that contribute to someone having a disease.

So far, the technology has thrown up around 200 genes associated with Parkinson’s, which ETX has further analysed using its Network-Driven Drug Discovery (NDD) approach.

“By using the advanced computational analytics of our NDD platform, we have been able to confirm the centrality of a number of known mechanisms in PD and, importantly, identify potential new ones,” said ETX’s head of discovery biology, Alan Whitmore.

“This in turn, opens up the prospect of new approaches to the discovery of effective novel drugs to tackle this and other undertreated, debilitating conditions.”

C4X’s chief scientific officer Craig Fox added: “This combination [with ETX] has identified additional novel biological pathways for the treatment of PD and we look forward to moving these findings forward to initiate new drug discovery programmes.”

While both companies believe this approach could help to identify better treatments for PD, they think it could also work for other degenerative disorders such as Alzheimer’s and multiple sclerosis.

View full ETX profile View Profile

e-Therapeutics plc Timeline

CN Video
March 28 2018

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use